Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Gaucher Disease

Abstract

Ito and Barrett recently reviewed the international experiences with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of the neuronopathic and non-neuronopathic forms of Gaucher disease (GD). In the present communication, the author adds some updated data on the long-term outcome of allo-HSCT for Swedish GD patients with the mean and median follow-up time of 27 years (the longest follow-up of 30 years) and makes comments on some of the authors’ statements found in the article.

Keywords :

• allogeneic
• Gaucher disease
• hematopoietic stem cell transplantation
• outcome